To convert the meeting times to your local time Click Here
Industry Hall 1
The advent of PARP inhibitors continues to change the treatment paradigm for ovarian cancer with emerging data, guideline updates, new approvals, and expanded indications occurring frequently and expected to continue into the future. Unfortunately, many healthcare professionals do not understand the changing landscape of ovarian cancer therapy, specifically their lack of confidence and experience using PARP inhibitors. This educational symposium aims to update HCPs on the latest clinical trial data, long-term benefits of treatment outcomes and the differences in safety and efficacy profiles of the approved PARP inhibitors.